Cancer screening coverage: bowel cancer - WMCA

The proportion of women in the resident population eligible for cervical screening aged 25 to 49 years at end of period reported who were screened adequately within the previous 3.5 years.RationaleBowel cancer screening supports early detection of cancer and polyps which are not cancers but may develop into cancers overtime. About one in 20 people in the UK will develop bowel cancer during their lifetime. This indicator provides an opportunity to incentivise screening promotion and other local initiatives to increase coverage of bowel cancer screening.Improvements in coverage would mean more bowel cancers are detected at earlier, more treatable stages, and more polyps are detected and removed, reducing the risk of bowel cancer developing.Definition of numeratorTested women (numerator) is the number of eligible women with a technically adequate screen within the previous 3.5 years.Definition of denominatorEligible population (denominator) is the number of men and women aged 60 to 74 years resident in the area (determined by postcode of residence) who are eligible for bowel cancer screening at a given point in time, excluding those whose recall has been ceased for clinical reasons (e.g. no functioning colon) or if they opt out of the programme.CaveatsData for ICBs are estimated from local authority data. In most cases ICBs are coterminous with local authorities, so the ICB figures are precise. In cases where local authorities cross ICB boundaries, the local authority data are proportionally split between ICBs, based on population located in each ICB.The affected ICBs are:Bath and North East Somerset, Swindon and Wiltshire;Bedfordshire, Luton and Milton Keynes;Buckinghamshire, Oxfordshire and Berkshire West;Cambridgeshire and Peterborough;Frimley;Hampshire and Isle of Wight;Hertfordshire and West Essex;Humber and North Yorkshire;Lancashire and South Cumbria;Norfolk and Waveney;North East and North Cumbria;Suffolk and North East Essex;Surrey Heartlands;Sussex;West Yorkshire.Please be aware that the April 2019 to March 2020, April 2020 to March 2021 and April 2021 to March 2022 data covers the time period affected by the COVID19 pandemic and therefore data for this period should be interpreted with caution.This indicator gives screening coverage by local authority of residence. This is not the same as the indicator based on population registered with primary care organisations which include patients wherever they live. This is likely to result in different England totals depending on selected (registered or resident) population footprint.The indicator excludes women outside the target age range for the screening programme who may self-refer for screening.The data for bowel screening indicators has been refreshed for all years, back to the 2013 to 2014 financial year. This is due to a methodology change, to ensure the data periods run up to the end of March in the given financial year.

本数据集旨在衡量居住人口中符合年龄在25至49岁之间进行宫颈癌筛查资格的女性比例，在报告期末，在过去的3.5年内已充分接受筛查的人数。理由：结直肠癌筛查有助于癌症和息肉的早期发现，尽管这些息肉并非癌症，但长期发展可能演变为癌症。在英国，大约每20人中就有1人将在其一生中患上结直肠癌。本指标为鼓励筛查推广和其他地方性倡议以增加结直肠癌筛查覆盖率提供了机会。覆盖率的提高意味着更多的结直肠癌能够在早期、更易治疗的阶段被发现，并且更多的息肉被发现并移除，从而降低结直肠癌发生的风险。分子定义：已筛查女性（分子）是指在过去3.5年内进行技术性充分筛查的合格女性数量。分母定义：合格人群（分母）是指在该特定时间点居住在该地区（由居住地的邮编确定）且符合结直肠癌筛查资格的60至74岁男女数量，不包括因临床原因（例如，无功能结肠）而停止召回或自愿退出该项目的个体。注意事项：ICBs的数据是根据地方当局数据估算得出的。在大多数情况下，ICBs与地方当局同期，因此ICB数据准确无误。在地方当局跨越ICB边界的情况下，地方当局数据将根据每个ICB内的居住人口比例分配给ICBs。受影响的ICBs包括：巴思和北东萨默塞特、斯旺西和威尔特郡；贝德福德郡、卢顿和米尔顿凯恩斯；白金汉郡、牛津郡和伯克郡西部；剑桥郡和彼得伯勒；弗里姆利；汉普郡和怀特岛；赫特福德郡和西埃塞克斯；赫尔伯恩和北约克郡；兰开夏郡和南坎布里亚；诺福克和韦恩尼；东北和南坎布里亚；萨福克和北东埃塞克斯；萨里心脏地带；萨塞克斯；西约克郡。请注意，2019年4月至2020年3月、2020年4月至2021年3月和2021年4月至2022年3月的数据覆盖了受COVID-19大流行影响的时期，因此应谨慎解读这一时期的数据。本指标提供了按居住地地方当局的筛查覆盖率。这不同于基于在初级保健组织中注册的居民人口所基于的指标。这可能导致根据所选（注册或居住）人口足迹的英格兰总数据不同。本指标排除了可能自行寻求筛查但不在筛查项目目标年龄范围内的女性。结直肠癌筛查指标的数据已更新至所有年份，直至2013-2014财年。这是由于方法论的变更，以确保数据周期延伸至该财年3月底。